c-MET-KIF5B (Kex24Mex14)

KIF5B-MET · Variant type: unknown

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Gilteritinib	90.5%	9.5%	88.97
2	Lenvatinib	89.4%	10.6%	97.74
3	Capmatinib	82.7%	17.3%	99.75
4	Tepotinib	80.3%	19.7%	99.75
5	Deucravacitinib	76.5%	23.5%	98.99
6	Tivozanib	75.4%	24.6%	92.42
7	Pacritinib	72.0%	28.0%	88.64
8	Regorafenib	71.0%	29.1%	95.99
9	Ibrutinib	68.6%	31.4%	94.74
10	Erdafitinib	60.7%	39.3%	95.71
11	Canertinib	59.2%	40.8%	96.49
12	Defactinib	57.5%	42.5%	92.68
13	Repotrectinib	47.8%	52.2%	84.21
14	Neratinib	41.9%	58.1%	93.18
15	Selpercatinib	39.1%	60.9%	96.72
16	Abemaciclib	38.8%	61.2%	91.48
17	Dacomitinib	33.1%	66.9%	97.99
18	Sunitinib	28.1%	71.9%	91.73
19	Cabozantinib	27.5%	72.5%	92.73
20	Pralsetinib	21.6%	78.4%	93.43
21	Fedratinib	20.0%	80.0%	96.21
22	Erlotinib	17.5%	82.5%	99.75
23	Avapritinib	16.5%	83.5%	97.73
24	Dabrafenib	15.8%	84.2%	94.74
25	Alectinib	15.7%	84.3%	95.49

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Gilteritinib	90.5%	—	—
Lenvatinib	89.4%	—	—
Capmatinib	82.7%	—	—
Tepotinib	80.3%	—	—
Deucravacitinib	76.5%	—	—
Tivozanib	75.4%	—	—
Pacritinib	72.0%	—	—
Regorafenib	71.0%	—	—
Ibrutinib	68.6%	—	—
Erdafitinib	60.7%	—	—
Canertinib	59.2%	—	—
Defactinib	57.5%	—	—
Repotrectinib	47.8%	—	—
Neratinib	41.9%	—	—
Selpercatinib	39.1%	—	—
Abemaciclib	38.8%	—	—
Dacomitinib	33.1%	—	—
Sunitinib	28.1%	—	—
Cabozantinib	27.5%	—	—
Pralsetinib	21.6%	—	—
Fedratinib	20.0%	—	—
Erlotinib	17.5%	—	—
Avapritinib	16.5%	—	—
Dabrafenib	15.8%	—	—
Alectinib	15.7%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 18.3ms